CAMP4 Therapeutics reports Q1 net loss $18.3M; files first CMP-002 regulatory submission in Australia

Camp4 Therapeutics Corp

2026-Q1 EPS reported -$0.32 vs consensus -$0.21 ▼ miss (-49.4%)

Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.
Net loss $18.3M vs $12.4M YoY, including $6.2M non-cash loss on derivative tranche liability.
Submitted first regulatory filing for CMP-002 (SYNGAP1) in Australia; global Phase 1/2 trial anticipated in 2H 2026.
EMA granted orphan designation for CMP-002; FDA ODD application pending.
Appointed Michael MacLean to Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Camp4 Therapeutics Corp reported the first quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3.

Period: the first quarter ended March 31, 2026
Net income: Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3
Result: reported results

Exact text from the filing

CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate highlights.

View on SEC.gov

Browse all earnings releases →

Camp4 Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001628280-26-032096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.